
|Articles|March 12, 2014
- Immunotherapy (Issue 2)
- Volume 2
- Issue 1
The Future of Immunotherapy Treatments in Lung Cancer
Author(s)Balazs Halmos, MD
Balazs Halmos, MD, section chief of Thoracic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the future of immunotherapy treatments.
Advertisement
Balazs Halmos, MD, section chief of Thoracic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the future of immunotherapy treatments in lung cancer.
Read more about immunotherapies for lung and other cancers > >
Articles in this issue
almost 12 years ago
The Outlook for CAR-Modified T Cellsalmost 12 years ago
B-Cell Malignancies Faring Well With Immunotherapiesalmost 12 years ago
Update on Immunotherapy and Targeted Combination Therapiesalmost 12 years ago
How Immunotherapies are Changing the Treatment of Melanomaalmost 12 years ago
Progress Made With PD-L1 as Predictive Biomarkeralmost 12 years ago
Oncolytic Viral Therapies About to Spreadalmost 12 years ago
Checking in on Checkpoint InhibitorsAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5









































